Abstract
Monkeys infected intravenously with a lethal dose of LCMV-WE provide a model for Lassa fever virus infection of man. Like Lassa fever in man, disease begins with flu-like symptoms and progresses rapidly to death within two weeks of infection. It is essential to correctly diagnose hemorrhagic fever rather than more benign viral diseases to provide the proper treatment. Microarray analyses were conducted on blood of macaques infected with virulent WE virus, and compared to gene expression in monkeys infected with non-virulent LCMV-ARM. We observed gene expression changes that occur before the viremic stage of the disease, and could potentially serve as biomarkers that discriminate between exposure to a hemorrhagic fever virus and exposure to a benign virus. In particular, transcription analysis revealed an early and severe suppression of the COX2 pathways indicating that disease treatments should avoid COX-inhibitors, like aspirin, and favor pathway stimulators.
Highlights
2006 International Meeting of The Institute of Human Virology Meeting abstracts
Monkeys infected intravenously with a lethal dose of LCMV-WE provide a model for Lassa fever virus infection of man
Like Lassa fever in man, disease begins with flulike symptoms and progresses rapidly to death within two weeks of infection
Summary
Transcription profiling of early responses to hemorrhagic fever in rhesus macaque M Djavani*1,2, O Crasta1,2, JC Zapata1,2, Z Fei1,2, O Folkerts1,2, B Sobral1,2, J Bryant1,2, C Pauza1,2, I Lukashevich1,2 and MS Salvato1,2 Address: 1Institute of Human Virology, University of Maryland Biotechnology Institute, Baltechnology Institute, Baltimore, Maryland, 21201, USA and 2Virginia Bioinformatics Institute, Blacksburg, Virgina, 24061, USA
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
